---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-031972"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2026-07-02T21:25:27+00:00"
generated_at: "2026-07-02T21:26:07.582290+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Akari Therapeutics AGM: Director James Neal not re-elected; committee appointments made

## Summary
- James Neal failed to receive requisite shareholder approval; his directorship ended at AGM conclusion.
- Board appointed Dr. Ray Prudo to Audit Committee and Robert Bazemore as Chair of Compensation Committee.
- All other 16 resolutions passed, including re-election of five directors and ratification of BDO as auditor.
- Shareholders approved issuance of shares under ELOC and warrants from May 20, 2026 private placement.

## SEC filing metadata
- accession: 0001493152-26-031972
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2026-07-02T21:25:27+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000149315226031972/0001493152-26-031972-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000149315226031972/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-031972
- JSON: https://secwatch.observer/filing/0001493152-26-031972.json
- Plain text: https://secwatch.observer/filing/0001493152-26-031972.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.